Oestrogen Receptor Positive Breast Cancer: Disease Bioinformatics
Breast cancer begins typically as a ductal carcinoma and can affect men or women. It is the second most commonly diagnosed cancer of women in the United States. Risk for developing breast cancer increases with age, family history, gene mutations on BRCA1 and BRCA2, obesity, radiation exposure, early onset of puberty, never having kids, postmenopausal hormone therapy, and excessive alcohol intake. Treatment for breast cancer includes: surgery, radiation therapy, chemotherapy, hormone therapy, alternative medicine, and medications. If the breast cancer cells have oestrogen receptors, the cancer is labeled ER positive. Oestrogen may trigger these breast cancers to develop by encouraging particular proteins in the cancer cells. ER positive breast cancers can be treated with hormone therapies that prevent cell growth and dividing. This form of therapy works to reduce the size of tumors before surgery or may be used to prevent it from coming back in the future.
Oestrogen Receptor Positive Breast Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Oestrogen Receptor Positive Breast Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 1956 products for the study of Oestrogen Receptor Positive Breast Cancer that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.